$AMLX News

Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome; Results Demonstrate Continued Improvements In Pancreatic Beta Cell Function Through Week 48

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Launches Early Access Program For Experimental Hypoglycemia Drug, Expands Access To Avexitide Ahead Of Phase 3 Results

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $21

Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment

Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?

HC Wainwright & Co. Reiterates Buy on Amylyx Pharmaceuticals, Maintains $34 Price Target

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals Says Last Participant Randomized And Dosed In Pivotal Phase 3 LUCIDITY Clinical Trial Of Avexitide

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $30

Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf.

Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...

Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $34